As described in note 1, we reorganized our segment reporting structure effective January 1, 2024. The segment reporting reorganization also resulted in a change to our reporting units for the purpose of goodwill impairment testing. Our new reporting units are Buy Sell Lab, Proprietary Lab, Services, Manufactured Products, Buy Sell Production, and NuSil. As a result of the reorganization, our goodwill was reassigned to the new reporting units making up our Laboratory Solutions and Bioscience Production reporting segments.

We have reassigned goodwill as of January 1, 2024 to align to our new segment structure by using a relative fair value approach. We tested goodwill for impairment immediately before and after the realignment; no impairment was identified.


	Laboratory Solutions		Bioscience Production		Total
Goodwill, gross	$	3,842.0	$	1,913.5	$	5,755.5
Accumulated impairment losses	(18.4)		(20.4)		(38.8)
Goodwill, net	$	3,823.6	$	1,893.1	$	5,716.7

The following table presents the components of other intangible assets:


(in millions)	June 30, 2024						December 31, 2023
	Gross value		Accumulated amortization and impairment1		Carrying value		Gross value		Accumulated amortization and impairment1		Carrying value
Customer relationships	$	4,822.3	$	1,772.0	$	3,050.3	$	4,883.2	$	1,670.3	$	3,212.9
Trade names	355.5		234.3		121.2		359.7		228.3		131.4
Other	631.3		312.3		319.0		635.5		296.8		338.7
Total finite-lived	$	5,809.1	$	2,318.6	3,490.5		$	5,878.4	$	2,195.4	3,683.0
Indefinite-lived					92.3						92.3
Total					$	3,582.8					$	3,775.3

1.As of June 30, 2024 and December 31, 2023, accumulated impairment losses on Customer relationships were $65.9 million and on Other were $40.5 million totaling $106.4 million.